Home › Treatment Guides › Mounjaro NHS 2026
Mounjaro NHS 2026: Complete Guide to Eligibility, Cohorts, Waiting Times & Private Options
Can’t Access NHS Mounjaro? Slinic Provides Private Access From £139 — No Waiting List
GPhC No. 1033729 · NHS-contracted · BMI 30+ or 27+ with qualifying condition · Same-day prescriber review · Next-day delivery to every UK postcode
- ✅ Private eligibility: BMI 30+ (or 27+ with T2D, hypertension, CVD, dyslipidaemia, sleep apnoea)
- ✅ Mounjaro 2.5mg £139 · 5mg £165 · 7.5mg £225 · 10mg £255 · 12.5mg £275 · 15mg £285
- ✅ No GP referral needed · No waiting list · Free monthly check-ins · £4.99 next-day delivery
- ✅ No subscription · No minimum term · Authorised Eli Lilly UK supply chain · SCOPE Obesity Accredited
Mounjaro on the NHS in 2026 is available — but access is complicated. The medication is approved by NICE (TA1026, December 2024), but NHS England has implemented a phased rollout that makes the criteria significantly more restrictive than NICE’s clinical recommendation. Your eligibility depends on your BMI, your qualifying conditions, and critically — whether your GP practice has opted in to the prescribing pathway. This guide explains all of it clearly, including the Cohort 2 expansion that launched on 23 June 2026.
The Three NHS Routes to Mounjaro in 2026
| Route | Who it covers | How to access | Waiting time | GP referral needed? |
|---|---|---|---|---|
| Route 1: QOF primary care — Cohort 1 | BMI 40+ (37.5+ ethnic) with ≥4 of 5 qualifying conditions | Ask your GP if their practice has adopted the QOF Mounjaro pathway. If yes, GP prescribes directly. | None if practice has adopted — variable if not | No referral — GP prescribes directly |
| Route 2: QOF primary care — Cohort 2 ⭐ NEW 23 Jun 2026 | BMI 35–39.9 (32.5–37.4 ethnic) with ≥4 of 5 qualifying conditions | Same as Cohort 1 — ask your GP if their practice has adopted the pathway | None if practice has adopted | No referral — GP prescribes directly |
| Route 3: NHS Tier 3 specialist weight management | BMI 35+ with ≥1 comorbidity (varies by ICB) — broader criteria than QOF but longer wait | GP referral to Tier 3 service. Multidisciplinary assessment (dietitian, psychologist, clinician). | 12–36 months typical — varies significantly by ICB | Yes — GP referral required |
NHS Cohort Criteria — The Full Breakdown
Cohort 1 (Active — launched March 2025)
To qualify for NHS primary care Mounjaro under Cohort 1, you must meet ALL of:
- BMI 40 kg/m² or above (adjusted to 37.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds)
- At least FOUR of the following five qualifying long-term conditions:
- Type 2 diabetes
- Hypertension (high blood pressure — diagnosed)
- Dyslipidaemia (high cholesterol — diagnosed)
- Established cardiovascular disease (prior heart attack, stroke, angina, or heart failure)
- Obstructive sleep apnoea (diagnosed, with or without CPAP)
Cohort 2 (Active from 23 June 2026) — NEW
Future cohorts — planned but not yet active
| Cohort | Planned start date | BMI threshold | Conditions required |
|---|---|---|---|
| Cohort 3 | April 2027 | 40+ (37.5+ ethnic) | 3 of 5 qualifying conditions (lower bar than Cohorts 1–2) |
| Cohort 4 | April 2028 (projected) | 35+ (32.5+ ethnic) | 2 of 5 qualifying conditions |
| Cohort 5 | TBC | 30+ (27.5+ ethnic) | 1 qualifying condition |
NICE TA1026 vs NHS England Commissioning — Why There’s a Gap
The most common source of confusion is the difference between what NICE has approved and what NHS England is actually prescribing.
| Factor | NICE TA1026 (clinical recommendation) | NHS England active commissioning |
|---|---|---|
| Minimum BMI | 35 (32.5 ethnic) | 40 (37.5 ethnic) — Cohort 1 / 35 (32.5) — Cohort 2 from June 2026 |
| Conditions required | At least ONE weight-related comorbidity | At least FOUR of five specific conditions |
| Why the difference? | Full clinical recommendation for population benefit | Phased rollout to manage NHS capacity and cost — estimated 3.4 million patients would qualify under full NICE criteria |
| When will it align? | Projected 2027–2030 as cohorts expand | Cohort 5 (projected) would align with NICE’s BMI 30+ recommendation |
The QOF T2D Pathway (April 2026)
Separate from the weight management cohorts, Mounjaro was incorporated into the NHS General Practice Quality and Outcomes Framework (QOF) for type 2 diabetes from April 2026. This matters because:
- T2D patients who meet NICE TA1026 criteria (BMI 35+ with T2D and ≥1 other condition) may be eligible through this pathway even if their BMI is below the Cohort 1 or 2 weight management threshold
- The QOF framework means Mounjaro is now part of standard diabetes management at GP level — not just a specialist medicine
- GP practices that have adopted the QOF T2D pathway can prescribe tirzepatide for T2D patients within their contracted NHS services
- Again — participation is optional. Your practice may not have adopted this pathway
NHS Tier 3 Weight Management Services — Regional Waiting Times
Tier 3 services are NHS-funded multidisciplinary weight management programmes providing medical, dietary, and psychological support. Mounjaro (and Wegovy) are available through these services. Access is via GP referral. Waiting times vary enormously by Integrated Care Board (ICB):
| Region | NHS ICB | Typical Tier 3 wait | Notes |
|---|---|---|---|
| London | All 5 London ICBs | 18–36 months | Highest demand in England — longest waits in South East and North East London |
| Manchester | Greater Manchester ICB | 12–24 months | Significant investment in Tier 3 — shorter waits than London but still significant |
| Birmingham | Birmingham and Solihull / Black Country | 18–30 months | High deprivation areas creating pressure on service capacity |
| Leeds / Bradford | West Yorkshire ICB | 12–20 months | Bradford has highest T2D rate in England — significant local demand |
| Liverpool / Merseyside | Cheshire and Merseyside ICB | 18–30 months | Knowsley has highest obesity rate in England — extreme pressure on capacity |
| Sheffield | South Yorkshire ICB | 12–20 months | Four districts with variable service availability |
| Nottingham | Nottingham and Nottinghamshire ICB | 12–24 months | Variable by local authority area within ICB |
| Bristol / BNSSG | NHS BNSSG ICB | 12–18 months | Among the shorter wait times in England — better-funded Tier 3 provision |
| Scotland | All NHS Scotland boards | 12–24 months | Free NHS prescriptions for all Scottish patients — different governance via SMC |
How to Access NHS Mounjaro — Step by Step
- Check your BMI and qualifying conditions against the cohort criteria above. Calculate your BMI using the NHS calculator and note which of the five conditions you have been diagnosed with.
- Book a GP appointment and ask two specific questions: (a) “Does our practice participate in the QOF tirzepatide/Mounjaro prescribing pathway?” and (b) “Do I meet the current cohort criteria based on my BMI and conditions?”
- If your practice has adopted the pathway and you meet criteria: your GP can prescribe Mounjaro directly. This is the fastest NHS route — no referral, no waiting list in most cases.
- If your practice has not adopted the pathway: ask for a referral to your local NHS Tier 3 weight management service. This is the alternative NHS route but involves a 12–36 month wait.
- If you don’t meet current NHS criteria or waiting times are too long: private prescribing at Slinic (BMI 30+ or 27+ with a qualifying condition) provides access within 48 hours at fixed 2026 prices from £139.
Access Mounjaro Now at Slinic — No NHS Wait Required
Free 2-minute assessment · BMI 30+ or 27+ with qualifying condition · Named prescriber review same day · GPhC No. 1033729
NHS Mounjaro vs Private Mounjaro — The Full Comparison
| Factor | NHS Mounjaro (QOF pathway) | Private Mounjaro (Slinic) |
|---|---|---|
| Cost | Free on prescription (standard prescription charge waived for Cohort 1/2) | £139–£285/month fixed — no hidden fees |
| Eligibility | BMI 40+ (Cohort 1) / 35–39.9 (Cohort 2) + 4 conditions + GP practice must opt in | BMI 30+ or 27+ with any qualifying condition |
| Waiting time | Variable — immediate if practice has pathway, months otherwise | 48 hours — no waiting list |
| GP referral | Not needed for QOF pathway — GP prescribes directly | Not needed — Slinic prescriber assesses independently |
| Clinical oversight | GP monitoring — depth varies by practice | Named Slinic prescriber + free monthly check-ins throughout treatment |
| Medication supply | NHS pharmacy — dispensing times vary | Next-day cold-chain tracked delivery to your UK address |
| Flexibility | Subject to NHS supply and prescription schedules | Order when you need · No subscription · No minimum term |
| Medication authenticity | NHS supply chain | Authorised Eli Lilly UK supply chain only — same medication |
Wegovy on the NHS in 2026 — Key Differences
Wegovy (semaglutide) follows a different NHS pathway from Mounjaro — understanding both helps you identify the most appropriate route:
| Factor | Mounjaro NHS 2026 | Wegovy NHS 2026 |
|---|---|---|
| Primary indication on NHS | Weight management (Cohort 1/2) + T2D (QOF) | Weight management (Tier 3) + Cardiovascular (April 2026 new pathway) |
| Cardiovascular pathway | Not yet approved for this indication — data expected 2026–2027 | Approved April 2026 for BMI 27+ with established CVD, no T2D — via GP referral |
| Weight loss evidence | 22.5% average (SURMOUNT-1) | 15% average (STEP 1) |
| Head-to-head result | 20.2% vs Wegovy 13.7% (SURMOUNT-5 2025) | 13.7% vs Mounjaro 20.2% (SURMOUNT-5 2025) |
| Slinic price from | £139 (2.5mg) | £99.99 (0.25mg) |
Frequently Asked Questions
Does my GP have to prescribe Mounjaro if I meet the NHS criteria?
No — and this is the most important thing to understand. The QOF Mounjaro pathway is voluntary for GP practices. Even if you perfectly meet Cohort 1 or Cohort 2 clinical criteria, your GP is not obligated to prescribe Mounjaro if their practice has not adopted the QOF pathway. The percentage of practices that have opted in varies significantly by region. If your practice has not adopted the pathway, your options are: ask to be referred to an NHS Tier 3 service, or access privately at Slinic from £139 without a GP referral.
What are the five qualifying conditions for NHS Mounjaro?
The five qualifying conditions for NHS primary care Mounjaro are: (1) type 2 diabetes, (2) hypertension (high blood pressure — diagnosed), (3) dyslipidaemia (high cholesterol — diagnosed), (4) established cardiovascular disease (prior heart attack, stroke, angina, or heart failure), and (5) obstructive sleep apnoea (diagnosed). For Cohorts 1 and 2, you need at least FOUR of these five. Cohort 3 (from April 2027) will require only three.
I have a BMI of 37 and type 2 diabetes — do I qualify for NHS Mounjaro in June 2026?
Potentially — from 23 June 2026, Cohort 2 covers BMI 35–39.9 with at least four qualifying conditions. With a BMI of 37 and T2D, you need three more qualifying conditions from: hypertension, dyslipidaemia, established CVD, or sleep apnoea. If you have these, you meet the Cohort 2 clinical criteria. However, you also need your GP practice to have adopted the QOF Mounjaro pathway — this is not universal. Speak to your GP. If your practice hasn’t adopted the pathway, Slinic can prescribe privately for you with BMI 37 and T2D — you easily meet private eligibility criteria.
Can I get NHS Mounjaro for weight loss without type 2 diabetes?
Yes — T2D is one of the five qualifying conditions, not the only one. You need four of the five. So if you have BMI 40+ with hypertension, dyslipidaemia, cardiovascular disease, and sleep apnoea — that is four conditions without T2D and qualifies you for Cohort 1. However, the QOF T2D pathway specifically requires T2D — that pathway is separate. The weight management cohorts (1 and 2) do not require T2D but do require four qualifying conditions from the full list of five.
What is the NHS Mounjaro waiting time?
For the QOF primary care pathway, there is no formal waiting time — if your GP practice has adopted the pathway and you meet criteria, they can prescribe at your appointment. However, many practices have not yet adopted the pathway, which effectively creates a wait until they do. For NHS Tier 3 weight management services, waiting times are typically 12–36 months depending on your region — with London, Liverpool, and Birmingham having the longest waits. Patients who cannot wait typically access privately at Slinic (48-hour turnaround from assessment to delivery).
Is NHS Mounjaro the same medication as private Mounjaro?
Yes — NHS and private Mounjaro is the same medication (tirzepatide) manufactured by Eli Lilly. Slinic sources exclusively from Eli Lilly’s authorised UK supply chain — the same supply chain used by NHS pharmacies. The medication, dose strengths, and KwikPen device are identical. The difference is simply the route of access and who bears the cost.
Official NHS and Regulatory References
Related Treatment Guides
Mounjaro Eligibility UK 2026Full private and NHS criteria explained
Weight Loss Injections on the NHSAll 3 NHS routes, regional waiting times
Cheapest Mounjaro UK 2026Full price comparison — all providers
Mounjaro Before and After UKClinical results, month-by-month timeline
Mounjaro vs Wegovy UK 2026SURMOUNT-5 head-to-head results
Don’t Wait for NHS Access — Start Mounjaro at Slinic Today
Same MHRA-licensed Mounjaro from Eli Lilly · GPhC No. 1033729 · Fixed 2026 prices · No waiting list · No GP referral needed
- ✅ Private eligibility: BMI 30+ or 27+ with qualifying condition — assessed same working day
- ✅ Mounjaro 2.5mg £139 → 15mg £285 · dispatched within 24 hours
- ✅ Free starter pack · Free monthly clinical check-ins · £4.99 next-day tracked delivery
- ✅ No subscription · No minimum term · NHS-contracted · SCOPE Obesity Accredited · LegitScript Certified
